ImmunityBio, Inc.
@ImmunityBio
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system.
According to the American Cancer Society, lung cancer accounts for nearly 1 in 5 cancer deaths in the United States. ImmunityBio is focused on developing therapies that address this ongoing health challenge. Read more: immunitybio.com/non-small-cell…
TONIGHT: @latimes and ImmunityBio Chairman @DrPatSoonShiong talks to Jon Stewart about curing cancer without chemotherapy and giving people a voice in their newspaper
Full interview with @DrPatSoonShiong: youtu.be/OtbRBfnkxRU
Protecting immune cells before radiation in #ProstateCancer treatment. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care >…
Our scientists translate rigorous immunology research into innovative cell- and immune-based therapies, working every day to expand treatment options and improve outcomes for patients.
Recombinant BCG addressing #BladderCancer treatment shortages. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access…
Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system, facilitating the attack and elimination of cancerous or infected cells today while building…
Today, we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent, ANKTIVA® (nogapendekin alfa inbakicept-pmln), in combination with Bacillus…
On this Independence Day, we recognize the sacrifices made for our freedom and the strength of the communities that continue to move our nation forward. The team at ImmunityBio wishes you a safe and happy holiday.
Bladder cancer recurrence is a reality for nearly half of patients with non-muscle invasive disease. ImmunityBio is advancing immunotherapy-based research to help the body's own defenses recognize and fight cancer. Learn more: immunitybio.com/bladder-cancer/
ResQ132A trial examines N-803 combinations for intermediate-risk #BladderCancer treatment. Bobby Reddy, MD @ImmunityBio joins @zklaassen_md @GACancerCenter to discuss ResQ132A, a trial tackling intermediate-risk #BladderCancer! Comparing BCG+N-803 vs. Gem+N-803, it aims to reduce…
Protecting immune cells before radiation in #ProstateCancer treatment. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care >…
Join us in transforming the future of cancer treatment. ImmunityBio is advancing innovative therapies that bring new hope to patients facing some of the most challenging cancers. We're looking for passionate, mission-driven individuals to grow with us. Be a part of something…
Recombinant BCG addressing #BladderCancer treatment shortages. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access…
Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness. We're working to address this challenge through our science…
We are happy to share that, as a proud sponsor of the SITC event at Buddy Guy’s Legends, we helped raise over $60,000 through the Forward Fund. These funds will directly support the programs, awards, and grants that advance the professional development of investigators, ensuring…
Annually, over 230,000 people in the United States are diagnosed with lung cancer, with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells, empowering the immune system to better combat NSCLC. Learn more about our…
Absolute lymphocyte count and neutrophil-to-lymphocyte ratios: Overlooked biomarkers in cancer treatment outcomes. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss research across multiple tumor types showing that patients maintaining ALC above 1,500 have…
Papillary non-muscle invasive #BladderCancer treatment guidelines gap. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss expanding ANKTIVA® (NAI) use to include papillary-only BCG-unresponsive bladder cancer. 📊 82% bladder preservation at 36 months 🧬…
"Smart therapies for difficult diseases" isn't just a phrase - it is the foundation of everything we do. At ImmunityBio, we're working to transform how cancer is treated by designing therapies that not only target disease, but restore the body's natural ability to fight it. View…